glp 1 news today glp-1 obesity drug updates New research is challenging long-held assumptions about FDA priority vouchers for GLP-1

This interaction sends signals to the brain suggesting fullness, subsequently decreasing the individuals appetite, leading to a reduction in food intake and aiding in weight loss

doi: 10.1111/j.1463-1326.2009.01194.x

Disclaimer: Results may vary

Recent labs are strongly recommended (but not required) prior to initiation of most weight loss medications

These include feeling nauseated, vomiting, diarrhea, upset stomach, headache, dizziness and a complete loss of appetite

EMPA-KIDNEY (Empagliflozin in Patients with Chronic Kidney Disease) showed that in patients with chronic kidney disease, empagliflozin leads to a lower risk of progression of kidney disease [29]